Search

Now showing items 11-14 of 14

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

Peter V., Coyle; Chemaitelly, Hiam; Ben Hadj Kacem, Mohamed Ali; Abdulla Al Molawi, Naema Hassan; El Kahlout, Reham Awni; ... more authors ... less authors ( Elsevier , 2021 , Article)

The study objective was to the assess level of detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens ...

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Chemaitelly, Hiam; Yassine, Hadi M.; Benslimane, Fatiha M.; Al Khatib, Hebah A.; Tang, Patrick; ... more authors ... less authors (2021 , Article)

The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...

Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: Mathematical modelling analyses

Ayoub, H.H.; Ayoub, Houssein H.; Chemaitelly, Hiam; Makhoul, Monia; Al Kanaani, Zaina; ... more authors ... less authors ( BMJ Publishing Group , 2021 , Article)

Background Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritising available doses on the basis of recipient ...

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.

Chemaitelly, Hiam; Tang, Patrick; Hasan, Mohammad R; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ... less authors ( Massachusetts Medical Society , 2021 , Article)

Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine ...